Skip to main content
SpringerLink
Log in

Primary Sclerosing Cholangitis (PSC)

  • Chapter
  • First Online:
Liver Immunology

  • 2474 Accesses

Abstract

Primary sclerosing cholangitis (PSC) is a chronic progressive cholestatic liver disease of unknown etiology. It is characterized by diffuse inflammation and fibrosis of bile ducts leading to strictures primarily in large- and medium-sized ducts of the biliary tree (fibro-obliterative cholangiopathy) [1, 2]. The cause is presumably immune-mediated and it is frequently associated with inflammatory bowel disease (IBD) with peculiar features (PSC-IBD). The progressive destruction of bile ducts may lead to liver cirrhosis requiring liver transplantation. In addition, episodes of recurrent cholangitis and hepatobiliary/colorectal malignancies are frequently complicating the clinical course of PSC [3, 4]. Although the characterization and understanding of the disease has improved substantially since its first descriptions in the mid-nineteenth century [5], effective medical therapy is still lacking and this disorder still represents a potentially severe disease with poor prognosis. So far no established pharmacological therapy improving survival of PSC exists, and ursodeoxycholic acid (UDCA) in combination with endoscopic interventions of dominant strictures is presently widely applied in clinical practice. Liver transplantation is the only established treatment of PSC in patients with end-stage liver disease, recurrent cholangitis, or high-grade cholangiocyte dysplasia.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med. 1995;332(14):924.

    PubMed  CAS  Google Scholar 

  2. Angulo P, Lindor KD. Primary sclerosing cholangitis. Hepatology. 1999;30(1):325.

    PubMed  CAS  Google Scholar 

  3. Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Lööf L, Danielsson A, Hultcrantz R, Lindgren S, Prytz H, Sandberg-Gertzén H, Almer S, Granath F, Broomé U. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol. 2002;36(3):321–7.

    PubMed  Google Scholar 

  4. Boberg KM, Lind GE. Primary sclerosing cholangitis and malignancy. Best Pract Res Clin Gastroenterol. 2011;25(6):753–64.

    PubMed  Google Scholar 

  5. Hoffman CEE. Verschluss der Gallenwege durch Verdickung der Wandungen. Arch Pathol Anat Physiol. 1867;49:206–15.

    Google Scholar 

  6. Molodecky NA, Kareemi H, Parab R, Barkema HW, Quan H, Myers RP, Kaplan GG. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology. 2011;53(5):1590.

    PubMed  Google Scholar 

  7. Bambha K, Kim WR, Talwalkar J, Torgerson H, Benson JT, Therneau TM, Loftus Jr EV, Yawn BP, Dickson ER, Melton III LJ. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology. 2003;125(5):1364.

    PubMed  Google Scholar 

  8. Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol. 2007;102(5):1042.

    PubMed  Google Scholar 

  9. Lindkvist B, Benito de Valle M, Gullberg B, Björnsson E. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology. 2010;52(2):571.

    PubMed  Google Scholar 

  10. Escorsell A, Pares A, Rodes J, et al. Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver. J Hepatol. 1994;21:787–91.

    PubMed  CAS  Google Scholar 

  11. Ang TL, Fock KM, Ng TM, et al. Clinical profile of primary sclerosing cholangitis in Singapore. J Gastroenterol Hepatol. 2002;17:908–13.

    PubMed  Google Scholar 

  12. Schrumpf E, Boberg KM. Epidemiology of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2001;15:553–62.

    PubMed  CAS  Google Scholar 

  13. Bergquist A, Lindberg G, Saarinen S, Broomé U. Increased prevalence of primary sclerosing cholangitis among first-degree relatives. J Hepatol. 2005;42:252–6.

    PubMed  Google Scholar 

  14. Bergquist A, Montgomery SM, Bahmanyar S, Olsson R, Danielsson A, Lindgren S. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2008;6:939–43.

    PubMed  Google Scholar 

  15. Mitchell SA, Thyssen M, Orchard TR, Jewell DP, Fleming KA, Chapman RW. Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study. Gut. 2002;51:567–73.

    PubMed  CAS  Google Scholar 

  16. Karlsen TH, Franke A, Melum E, Kaser A, Hov JR, Balschun T, et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology. 2010;138:1102–11.

    PubMed  Google Scholar 

  17. Melum E, Franke A, Schramm C, Weismüller TJ, Gotthardt DN, et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet. 2011;43(1):17–9.

    PubMed  CAS  Google Scholar 

  18. Ellinghaus D, Folseraas T, Holm K, Ellinghaus E, Melum E, et al. Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4. Hepatology. 2013;58(3):1074–83. doi:10.1002/hep.25977.

    PubMed  CAS  Google Scholar 

  19. Chapman RW, Varghese Z, Gaul R, Patel G, Kokinon N, Sherlock S. Association of primary sclerosing cholangitis with HLA-B8. Gut. 1983;24:38–41.

    PubMed  CAS  Google Scholar 

  20. Leidenius MH, Koskimies SA, Kellokumpu IH, Höckerstedt KA. HLA antigens in ulcerative colitis and primary sclerosing cholangitis. APMIS. 1995;103:519–24.

    PubMed  CAS  Google Scholar 

  21. Jeffrey GP, Reed WD, Laurence BH, Shilkin KB. Primary sclerosing cholangitis: clinical and immunopathological review of 21 cases. J Gastroenterol Hepatol. 1990;5:135–40.

    PubMed  CAS  Google Scholar 

  22. Spurkland A, Saarinen S, Boberg KM, Mitchell S, Broome U, Caballeria L, et al. HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens. 1999;53:459–69.

    PubMed  CAS  Google Scholar 

  23. Farrant JM, Doherty DG, Donaldson PT, Vaughan RW, Hayllar KM, Welsh KI, et al. Amino acid substitutions at position 38 of the DR beta polypeptide confer susceptibility to and protection from primary sclerosing cholangitis. Hepatology. 1992;16:390–5.

    PubMed  CAS  Google Scholar 

  24. Donaldson PT. Genetics of liver disease: immunogenetics and disease pathogenesis. Gut. 2004;53:599–608.

    PubMed  CAS  Google Scholar 

  25. Moloney MM, Thomson LJ, Strettell MJ, Williams R, Donaldson PT. Human leukocyte antigen-C genes and susceptibility to primary sclerosing cholangitis. Hepatology. 1998;28:660–2.

    PubMed  CAS  Google Scholar 

  26. Norris S, Kondeatis E, Collins R, Satsangi J, Clare M, Chapman R, et al. Mapping MHC-encoded susceptibility and resistance in primary sclerosing cholangitis: the role of MICA polymorphism. Gastroenterology. 2001;120:1475–82.

    PubMed  CAS  Google Scholar 

  27. Wiencke K, Spurkland A, Schrumpf E, Boberg KM. Primary sclerosing cholangitis is associated to an extended B8-DR3 haplotype including particular MICA and MICB alleles. Hepatology. 2001;34:625–30.

    PubMed  CAS  Google Scholar 

  28. Mitchell SA, Grove J, Spurkland A, Boberg KM, Fleming KA, Day CP, et al. Association of the tumour necrosis factor alpha −308 but not the interleukin 10-627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis. Gut. 2001;49:288–94.

    PubMed  CAS  Google Scholar 

  29. Hov JR, Keitel V, Laerdahl JK, Spomer L, Ellinghaus E, ElSharawy A, et al. Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS One. 2010;5:e12403.

    PubMed  Google Scholar 

  30. Pauli-Magnus C, Kerb R, Fattinger K, Lang T, Anwald B, Kullak-Ublick GA, et al. BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology. 2004;39:779–91.

    PubMed  CAS  Google Scholar 

  31. Durieu I, Pellet O, Simonot L, Durupt S, Bellon G, Durand DV, Minh VA. Sclerosing cholangitis in adults with cystic fibrosis: a magnetic resonance cholangiographic prospective study. J Hepatol. 1999;30(6):1052–6.

    PubMed  CAS  Google Scholar 

  32. Girodon E, Sternberg D, Chazouillères O, Cazeneuve C, Huot D, Calmus Y, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene defects in patients with primary sclerosing cholangitis. J Hepatol. 2002;37:192–7.

    PubMed  CAS  Google Scholar 

  33. Henckaerts L, Jaspers M, Van Steenbergen W, Vliegen L, Fevery J, Nuytten H, et al. Cystic fibrosis transmembrane conductance regulator gene polymorphisms in patients with primary sclerosing cholangitis. J Hepatol. 2009;50:150–7.

    PubMed  CAS  Google Scholar 

  34. Pollheimer MJ, Halilbasic E, Fickert P, Trauner M. Pathogenesis of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2011;25(6):727–39.

    PubMed  CAS  Google Scholar 

  35. Chapman R, Cullen S. Etiopathogenesis of primary sclerosing cholangitis. World J Gastroenterol. 2008;14:3350–9.

    PubMed  CAS  Google Scholar 

  36. O’Mahony CA, Vierling JM. Etiopathogenesis of primary sclerosing cholangitis. Semin Liver Dis. 2006;26:3–21.

    PubMed  Google Scholar 

  37. Lichtman SN, Sartor RB. Hepatobiliary injury associated with experimental small-bowel bacterial overgrowth in rats. Immunol Res. 1991;10:528–31.

    PubMed  CAS  Google Scholar 

  38. Yamada S, Ishii M, Liang LS, Yamamoto T, Toyota T. Small duct cholangitis induced by N-formyl L-methionine L-leucine L-tyrosine in rats. J Gastroenterol. 1994;29:631–6.

    PubMed  CAS  Google Scholar 

  39. Olsson R, Björnsson E, Bäckman L, Friman S, Höckerstedt K, Kaijser B, et al. Bile duct bacterial isolates in primary sclerosing cholangitis: a study of explanted livers. J Hepatol. 1998;28:426–32.

    PubMed  CAS  Google Scholar 

  40. Björnsson E, Cederborg A, Akvist A, Simren M, Stotzer PO, Bjarnason I. Intestinal permeability and bacterial growth of the small bowel in patients with primary sclerosing cholangitis. Scand J Gastroenterol. 2005;40:1090–4.

    PubMed  Google Scholar 

  41. Mistilis SP, Skyring AP, Goulston SJ. Effect of long-term tetracycline therapy, steroid therapy and colectomy in pericholangitis associated with ulcerative colitis. Australas Ann Med. 1965;14:286–94.

    PubMed  CAS  Google Scholar 

  42. Färkkilä M, Karvonen AL, Nurmi H, Nuutinen H, Taavitsainen M, Pikkarainen P, et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology. 2004;40:1379–86.

    PubMed  Google Scholar 

  43. Palmer KR, Duerden BI, Holdsworth CD. Bacteriological and endotoxin studies in cases of ulcerative colitis submitted to surgery. Gut. 1980;21:851–4.

    PubMed  CAS  Google Scholar 

  44. Grant AJ, Lalor PF, Salmi M, Jalkanen S, Adams DH. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet. 2002;359:150–7.

    PubMed  Google Scholar 

  45. Eksteen B, Miles AE, Grant AJ, Adams DH. Lymphocyte homing in the pathogenesis of extra-intestinal manifestations of inflammatory bowel disease. Clin Med. 2004;4:173–80.

    PubMed  Google Scholar 

  46. Eksteen B, Mora JR, Haughton EL, Henderson NC, Lee-Turner L, Villablanca EJ, et al. Gut homing receptors on CD8 T cells are retinoic acid dependent and not maintained by liver dendritic or stellate cells. Gastroenterology. 2009;137:320–9.

    PubMed  CAS  Google Scholar 

  47. Grant AJ, Lalor PF, Hübscher SG, Briskin M, Adams DH. MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). Hepatology. 2001;33:1065–72.

    PubMed  CAS  Google Scholar 

  48. Aron JH, Bowlus CL. The immunobiology of primary sclerosing cholangitis. Semin Immunopathol. 2009;31:383–97.

    PubMed  CAS  Google Scholar 

  49. Van den Oord JJ, Sciot R, Desmet VJ. Expression of MHC products by normal and abnormal bile duct epithelium. J Hepatol. 1986;3:310–7.

    PubMed  Google Scholar 

  50. Lazaridis KN, Strazzabosco M, Larusso NF. The cholangiopathies: disorders of biliary epithelia. Gastroenterology. 2004;127:1565–77.

    PubMed  CAS  Google Scholar 

  51. Bo X, Broome U, Remberger M, Sumitran-Holgersson S. Tumour necrosis factor alpha impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis. Gut. 2001;49:131–41.

    PubMed  CAS  Google Scholar 

  52. Whiteside TL, Lasky S, Si L, Van Thiel DH. Immunologic analysis of mononuclear cells in liver tissues and blood of patients with primary sclerosing cholangitis. Hepatology. 1985;5:468–74.

    PubMed  CAS  Google Scholar 

  53. Hashimoto E, Lindor KD, Homburger HA, Dickson ER, Czaja AJ, Wiesner RH, et al. Immunohistochemical characterization of hepatic lymphocytes in primary biliary cirrhosis in comparison with primary sclerosing cholangitis and autoimmune chronic active hepatitis. Mayo Clin Proc. 1993;68:1049–55.

    PubMed  CAS  Google Scholar 

  54. Angulo P, Peter JB, Gershwin ME, DeSotel CK, Shoenfeld Y, Ahmed AE, et al. Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol. 2000;32:182–7.

    PubMed  CAS  Google Scholar 

  55. Terjung B, Worman HJ. Anti-neutrophil antibodies in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2001;15:629–42.

    PubMed  CAS  Google Scholar 

  56. Terjung B, Spengler U. Atypical p-ANCA in PSC and AIH: a hint toward a “leaky gut”? Clin Rev Allergy Immunol. 2009;36:40–51.

    PubMed  CAS  Google Scholar 

  57. Xu B, Broome U, Ericzon BG, Sumitran-Holgersson S. High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6. Gut. 2002;51:120–7.

    PubMed  CAS  Google Scholar 

  58. Karrar A, Broomé U, Södergren T, Jaksch M, Bergquist A, Björnstedt M, et al. Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis. Gastroenterology. 2007;132:1504–14.

    PubMed  CAS  Google Scholar 

  59. Pollheimer MJ, Trauner M, Fickert P. Will we ever model PSC?—“It’s hard to be a PSC model!”. Clin Res Hepatol Gastroenterol. 2011;35(12):792–804.

    PubMed  Google Scholar 

  60. Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter L, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell. 1993;75:451–62.

    PubMed  CAS  Google Scholar 

  61. Fickert P, Fuchsbichler A, Wagner M, Zollner G, Kaser A, Tilg H, et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology. 2004;127:261–74.

    PubMed  CAS  Google Scholar 

  62. Durie PR, Kent G, Phillips MJ, Ackerley CA. Characteristic multiorgan pathology of cystic fibrosis in a long-living cystic fibrosis transmembrane regulator knockout murine model. Am J Pathol. 2004;164:1481–93.

    PubMed  Google Scholar 

  63. Meerman L, Koopen NR, Bloks V, Van Goor H, Havinga R, Wolthers BG, et al. Biliary fibrosis associated with altered bile composition in a mouse model of erythropoietic protoporphyria. Gastroenterology. 1999;117:696–705.

    PubMed  CAS  Google Scholar 

  64. Libbrecht L, Meerman L, Kuipers F, Roskams T, Desmet V, Jansen P. Liver pathology and hepatocarcinogenesis in a long-term mouse model of erythropoietic protoporphyria. J Pathol. 2003;199:191–200.

    PubMed  Google Scholar 

  65. Trauner M, Fickert P, Wagner M. MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin Liver Dis. 2007;27:77–98.

    PubMed  CAS  Google Scholar 

  66. Fickert P, Stöger U, Fuchsbichler A, Moustafa T, Marschall HU, Weiglein AH, et al. A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis. Am J Pathol. 2007;171:525–36.

    PubMed  CAS  Google Scholar 

  67. Lyoumi S, Abitbol M, Rainteau D, Karim Z, Bernex F, Oustric V, et al. Protoporphyrin retention in hepatocytes and Kupffer cells prevents sclerosing cholangitis in erythropoietic protoporphyria mouse model. Gastroenterology. 2011;141(4):1509–19.

    PubMed  CAS  Google Scholar 

  68. Fickert P, Fuchsbichler A, Marschall HU, Wagner M, Zollner G, Krause R, et al. Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. Am J Pathol. 2006;168:410–22.

    PubMed  CAS  Google Scholar 

  69. Rasmussen HH, Fallingborg JF, Mortensen PB, et al. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn’s disease. Scand J Gastroenterol. 1997;32:604.

    PubMed  CAS  Google Scholar 

  70. Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis. 1991;11:31–9.

    PubMed  CAS  Google Scholar 

  71. Gow PJ, Chapman RW. Liver transplantation for primary sclerosing cholangitis. Liver. 2000;20:97–103.

    PubMed  CAS  Google Scholar 

  72. Aadland E, Schrumpf E, Fausa O, Elgjo K, Heilo A, Aakhus T, et al. Primary sclerosing cholangitis: a long-term follow-up study. Scand J Gastroenterol. 1987;22:655–64.

    PubMed  CAS  Google Scholar 

  73. Dave M, Elmunzer BJ, Dwamena BA, et al. Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography. Radiology. 2010;256:387–96.

    PubMed  Google Scholar 

  74. Talwalkar JA, Angulo P, Johnson CD, et al. Cost minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. Hepatology. 2004;40:39–45.

    PubMed  Google Scholar 

  75. Wiencke K, Boberg KM. Current consensus on the management of primary sclerosing cholangitis. Clin Res Hepatol Gastroenterol. 2011;35(12):786–91.

    PubMed  CAS  Google Scholar 

  76. Krones E, Graziadei I, Trauner M, Fickert P. Evolving concepts in primary sclerosing cholangitis. Liver Int. 2012;32(3):352–69.

    PubMed  CAS  Google Scholar 

  77. Cullen SN, Chapman RW. The medical management of primary sclerosing cholangitis. Semin Liver Dis. 2006;26(1):52–61.

    PubMed  CAS  Google Scholar 

  78. Loftus Jr EV, Harewood GC, Loftus CG, Tremaine WJ, Harmsen WS, Zinsmeister AR, Jewell DA, Sandborn WJ. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005;54(1):91–6.

    PubMed  Google Scholar 

  79. Fevery J, Henckaerts L, Van Oirbeek R, et al. Malignancies and mortality in 200 patients with primary sclerosing cholangitis: a long-term single centre study. Liver Int. 2012;32:214–22.

    PubMed  Google Scholar 

  80. Bjornsson E, Olsson R, Bergquist A, et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology. 2008;134:975–80.

    PubMed  Google Scholar 

  81. Bjornsson E, Boberg KM, Cullen S, et al. Patients with small duct primary sclerosing cholangitis have a favorable long term prognosis. Gut. 2002;51:731–5.

    PubMed  CAS  Google Scholar 

  82. Mendes FD, Jorgensen R, Keach J, Katzmann JA, Smyrk T, Donlinger J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2006;101:2070–5.

    PubMed  CAS  Google Scholar 

  83. Björnsson E, Chari S, Silveira M, Gossard A, Takahashi N, Smyrk T, et al. Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. Am J Ther. 2011;18:198–205.

    PubMed  Google Scholar 

  84. Oseini AM, Chaiteerakij R, Shire AM, Ghazale A, Kaiya J, Moser CD, Aderca I, Mettler TA, Therneau TM, Zhang L, Takahashi N, Chari ST, Roberts LR. Utility of serum immunoglobulin G4 distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma. Hepatology. 2011;54(3):940–8.

    PubMed  CAS  Google Scholar 

  85. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ; American Association for the Study of Liver Diseases. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51(2):660–78.

    Google Scholar 

  86. Alswat K, Al-Harthy N, Mazrani W, Alshumrani G, Jhaveri K, Hirschfield GM. The spectrum of sclerosing cholangitis and the relevance of IgG4 elevations in routine practice. Am J Gastroenterol. 2012;107(1):56–63.

    PubMed  CAS  Google Scholar 

  87. Zhang L, Lewis JT, Abraham SC, et al. IgG4+ plasma cell infiltrates in liver explants with primary sclerosing cholangitis. Am J Surg Pathol. 2010;34:88–94.

    PubMed  Google Scholar 

  88. Harnois DM, Gores GJ, Ludwig J, Steers JL, LaRusso NF, Wiesner RH. Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer? [Case Reports Clinical Trial Controlled Clinical Trial Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.]. J Hepatol. 1997;27(3):512–6.

    PubMed  CAS  Google Scholar 

  89. Razumilava N, Gores GJ, Lindor KD. Cancer surveillance in patients with primary sclerosing cholangitis [Review]. Hepatology. 2011;54(5):1842–52.

    PubMed  Google Scholar 

  90. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al. Diagnosis and management of primary sclerosing cholangitis [Practice Guideline]. Hepatology. 2010;51(2):660–78.

    PubMed  CAS  Google Scholar 

  91. European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases [Practice Guideline]. J Hepatol. 2009;51(2):237–67.

    Google Scholar 

  92. Rosen CB, Nagorney DM. Cholangiocarcinoma complicating primary sclerosing cholangitis [Review]. Semin Liver Dis. 1991;11(1):26–30.

    PubMed  CAS  Google Scholar 

  93. Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol. 2004;99(3):523–6.

    PubMed  Google Scholar 

  94. Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR. High lifetime risk of cancer in primary sclerosing cholangitis [Multicenter Study]. J Hepatol. 2009;50(1):158–64.

    PubMed  Google Scholar 

  95. Bangarulingam SY, Bjornsson E, Enders F, Barr Fritcher EG, Gores G, Halling KC, et al. Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology. 2010;51(1):174–80.

    PubMed  CAS  Google Scholar 

  96. Shen J, Wang W, Wu J, Feng B, Chen W, Wang M, et al. Comparative proteomic profiling of human bile reveals SSP411 as a novel biomarker of cholangiocarcinoma [Research Support, Non-U.S. Gov’t]. PLoS One. 2012;7(10):e47476.

    PubMed  CAS  Google Scholar 

  97. Metzger J, Negm AA, Plentz RR, Weismuller TJ, Wedemeyer J, Karlsen TH, et al. Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut. 2013;62(1):122–30.

    PubMed  CAS  Google Scholar 

  98. Chalasani N, Baluyut A, Ismail A, Zaman A, Sood G, Ghalib R, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case–control study [Multicenter Study Research Support, Non-U.S. Gov’t]. Hepatology. 2000;31(1):7–11.

    PubMed  CAS  Google Scholar 

  99. Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case–control study. Gastroenterology. 2005;128(3):620–6.

    PubMed  Google Scholar 

  100. Al Mamari S, Djordjevic J, Halliday JS, Chapman RW. Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol. 2013;58(2):329–34.

    PubMed  CAS  Google Scholar 

  101. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma [Review]. Lancet. 2005;366(9493):1303–14.

    PubMed  Google Scholar 

  102. Jarnagin WR, Shoup M. Surgical management of cholangiocarcinoma [Review]. Semin Liver Dis. 2004;24(2):189–99.

    PubMed  Google Scholar 

  103. Brandsaeter B, Isoniemi H, Broome U, Olausson M, Backman L, Hansen B, et al. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol. 2004;40(5):815–22.

    PubMed  CAS  Google Scholar 

  104. Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients [Meta-Analysis Research Support, U.S. Gov’t, Non-P.H.S.]. Transplantation. 2000;69(8):1633–7.

    PubMed  CAS  Google Scholar 

  105. Rosen CB, Heimbach JK, Gores GJ. Liver transplantation for cholangiocarcinoma [Review]. Transpl Int. 2010;23(7):692–7.

    PubMed  Google Scholar 

  106. Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. [Multicenter Study Research Support, Non-U.S. Gov’t] 2012;143(1):88–98e3; quiz e14.

    Google Scholar 

  107. De Vreede I, Steers JL, Burch PA, Rosen CB, Gunderson LL, Haddock MG, et al. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma [Research Support, Non-U.S. Gov’t]. Liver Transpl. 2000;6(3):309–16.

    PubMed  Google Scholar 

  108. Murad SD, Kim WR, Therneau T, Gores GJ, Rosen CB, Martenson JA, et al. Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma [Research Support, Non-U.S. Gov’t]. Hepatology. 2012;56(3):972–81.

    Google Scholar 

  109. Khorsandi SE, Salvans S, Zen Y, Agarwal K, Jassem W, Heaton N. Cholangiocarcinoma complicating recurrent primary sclerosing cholangitis after liver transplantation [Case Reports]. Transpl Int. 2011;24(10):e93–6.

    PubMed  Google Scholar 

  110. Landaverde C, Ng V, Sato A, Tabibian J, Durazo F, Busuttil R. De-novo cholangiocarcinoma in native common bile duct remnant following OLT for primary sclerosing cholangitis [Case Reports]. Ann Hepatol. 2009;8(4):379–83.

    PubMed  Google Scholar 

  111. Said K, Glaumann H, Bergquist A. Gallbladder disease in patients with primary sclerosing cholangitis [Comparative Study]. J Hepatol. 2008;48(4):598–605.

    PubMed  Google Scholar 

  112. Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder [Review]. Lancet Oncol. 2003;4(3):167–76.

    PubMed  Google Scholar 

  113. Eaton JE, Thackeray EW, Lindor KD. Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis. Am J Gastroenterol. 2012;107(3):431–9.

    PubMed  Google Scholar 

  114. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis [Comparative Study Meta-Analysis Research Support, Non-U.S. Gov’t]. Gastrointest Endosc. 2002;56(1):48–54.

    PubMed  Google Scholar 

  115. Thackeray EW, Charatcharoenwitthaya P, Elfaki D, Sinakos E, Lindor KD. Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2011;9(1):52–6.

    PubMed  Google Scholar 

  116. Pardi DS, Loftus Jr EV, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis [Clinical Trial Randomized Controlled Trial]. Gastroenterology. 2003;124(4):889–93.

    PubMed  CAS  Google Scholar 

  117. Eaton JE, Silveira MG, Pardi DS, Sinakos E, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis [Randomized Controlled Trial Research Support, N.I.H., Extramural]. Am J Gastroenterol. 2011;106(9):1638–45.

    PubMed  CAS  Google Scholar 

  118. Imam MH, Sinakos E, Gossard AA, Kowdley KV, Luketic VA, Edwyn Harrison M, et al. High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis [Research Support, N.I.H., Extramural]. Aliment Pharmacol Ther. 2011;34(10):1185–92.

    PubMed  CAS  Google Scholar 

  119. Chan EP, Lichtenstein GR. Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease [Review]. Gastroenterol Clin North Am. 2006;35(3):675–712.

    PubMed  Google Scholar 

  120. Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study [Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. Gastroenterology. 2005;129(5):1464–72.

    PubMed  CAS  Google Scholar 

  121. Rudolph G, Kloeters-Plachky P, Rost D, Stiehl A. The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid. Eur J Gastroenterol Hepatol. 2007;19(6):487–91.

    PubMed  CAS  Google Scholar 

  122. Trauner M, Graziedei I. Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment Pharmacol Ther. 1999;13(8):979–96.

    PubMed  CAS  Google Scholar 

  123. Chazouilleres O, Poupon R, et al. Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol. 1990;11(1):120–3.

    PubMed  CAS  Google Scholar 

  124. O’Brien CB, Senior JR, et al. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology. 1991;14(5):838–47.

    PubMed  Google Scholar 

  125. Lebovics E, Salama M, et al. Resolution of radiographic abnormalities with ursodeoxycholic acid therapy of primary sclerosing cholangitis. Gastroenterology. 1992;102(6):2143–7.

    PubMed  CAS  Google Scholar 

  126. Beuers U, Spengler U, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology. 1992;16(3):707–14.

    PubMed  CAS  Google Scholar 

  127. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med. 1997;336(10):691–5.

    PubMed  CAS  Google Scholar 

  128. Mitchell SA, Bansi DS, et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology. 2001;121(4):900–7.

    PubMed  CAS  Google Scholar 

  129. Harnois DM, Angulo P, et al. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol. 2001;96(5):1558–62.

    PubMed  CAS  Google Scholar 

  130. Lindor KD, Kowdley KV, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50(3):808–14.

    PubMed  CAS  Google Scholar 

  131. Farkkila M, Karvonen AL, et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology. 2004;40(6):1379–86.

    PubMed  Google Scholar 

  132. van Hoogstraten HJ, Vleggaar FP, et al. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group. Am J Gastroenterol. 2000;95(8):2015–22.

    PubMed  Google Scholar 

  133. Fickert P, Wagner M, et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology. 2006;130(2):465–81.

    PubMed  CAS  Google Scholar 

  134. Halilbasic E, Fiorotto R, et al. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2−/− mice. Hepatology. 2009;49(6):1972–81.

    PubMed  CAS  Google Scholar 

  135. Moustafa T, Fickert P, et al. Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. Gastroenterology. 2012;142(1):140–51 e112.

    Google Scholar 

  136. Beuers U, Hohenester S, et al. The biliary HCO(3)(−) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology. 2010;52(4):1489–96.

    PubMed  CAS  Google Scholar 

  137. Beuers U, Maroni L, et al. The biliary HCO(3)(−) umbrella: experimental evidence revisited. Curr Opin Gastroenterol. 2012;28(3):253–7.

    PubMed  CAS  Google Scholar 

  138. Hohenester S, Wenniger LM, et al. A biliary HCO3-umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology. 2012;55(1):173–83.

    PubMed  CAS  Google Scholar 

  139. Trauner M, Claudel T, et al. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis. 2010;28(1):220–4.

    PubMed  Google Scholar 

  140. Halilbasic E, Claudel T, et al. Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J Hepatol. 2013;58(1):155–68.

    PubMed  CAS  Google Scholar 

  141. Cho WK, Boyer JL. Vasoactive intestinal polypeptide is a potent regulator of bile secretion from rat cholangiocytes. Gastroenterology. 1999;117(2):420–8.

    PubMed  CAS  Google Scholar 

  142. Chignard N, Mergey M, et al. VPAC1 expression is regulated by FXR agonists in the human gallbladder epithelium. Hepatology. 2005;42(3):549–57.

    PubMed  CAS  Google Scholar 

  143. Kim I, Morimura K, et al. Spontaneous hepatocarcinogenesis in farnesoid X receptor null mice. Carcinogenesis. 2007;28(5):940–6.

    PubMed  CAS  Google Scholar 

  144. Wang YD, Chen WD, et al. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology. 2008;48(5):1632–43.

    PubMed  CAS  Google Scholar 

  145. Li YT, Swales KE, et al. Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler Thromb Vasc Biol. 2007;27(12):2606–11.

    PubMed  Google Scholar 

  146. Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen EC, Renooij W, Murzilli S, Klomp LW, Siersema PD, Schipper ME, Danese S, Penna G, Laverny G, Adorini L, Moschetta A, van Mil SW. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut. 2011;60(4):463–72. doi:10.1136/gut.2010.212159.

    PubMed  CAS  Google Scholar 

  147. Inagaki T, Moschetta A, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A. 2006;103(10):3920–5.

    PubMed  CAS  Google Scholar 

  148. Modica S, Petruzzelli M, et al. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology. 2012;142(2):355–65.e1–4.

    Google Scholar 

  149. Mason A, Luketic V, et al. Farnesoid-X receptor agonists: a new class of drugs for the treatment of PBC? An international study evaluating the addition of obeticholic acid (INT-747) to ursodeoxycholic acid. Hepatology. 2010;52(Suppl S1):357A.

    Google Scholar 

  150. Hirschfield G, Mason A, et al. A long term safety extension trial of the farnesoid X receptor (FXR) agonist obeticholic acid (OCA) and UDCA in primary biliary cirrhosis (PBC). Hepatology. 2011;54(S1):429A.

    Google Scholar 

  151. Kowdley J, et al. An international study evaluating the farnesoid X receptor agonist obeticholic acid as monotherapy in PBC. J Hepatol. 2012;54(S1):S13.

    Google Scholar 

  152. Baghdasaryan A, Claudel T, et al. Dual FXR/TGR5 agonist INT-767 reduces liver injury in the Mdr2−/− (Abcb4−/−) mouse cholangiopathy model by promoting biliary HCO3− output. Hepatology. 2011;54(4):1303–12.

    PubMed  CAS  Google Scholar 

  153. Cox KL, Cox KM. Oral vancomycin: treatment of primary sclerosing cholangitis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1998;27(5):580–3.

    PubMed  CAS  Google Scholar 

  154. Silveira MG, Torok NJ, et al. Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study. Am J Gastroenterol. 2009;104(1):83–8.

    PubMed  CAS  Google Scholar 

  155. Pall H, Zaman MM, et al. Decreased peroxisome proliferator activated receptor alpha is associated with bile duct injury in cystic fibrosis transmembrane conductance regulator−/− mice. J Pediatr Gastroenterol Nutr. 2006;42(3):275–81.

    PubMed  CAS  Google Scholar 

  156. Martin CR, Blanco PG, et al. The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis—a pilot study. Aliment Pharmacol Ther. 2012;35(2):255–65.

    PubMed  CAS  Google Scholar 

  157. Stiehl A, Rudolph G, Kloters-Plachky P, et al. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol. 2002;36:151–6.

    PubMed  Google Scholar 

  158. Kaya M, Petersen BT, Angulo P, et al. Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol. 2001;96:1059–66.

    PubMed  CAS  Google Scholar 

  159. Bjoro K, Brandsaeter B, Foss A, Schrumpf E. Liver transplantation in primary sclerosing cholangitis. Semin Liver Dis. 2006;26(1):69–79.

    PubMed  Google Scholar 

  160. Graziadei IW, Wiesner RH, Marotta PJ, Porayko MK, Hay JE, Charlton MR, et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology. 1999;30(5):1121–7.

    PubMed  CAS  Google Scholar 

  161. Aberg F, Hockerstedt K, Roine RP, Sintonen H, Isoniemi H. Influence of liver-disease etiology on long-term quality of life and employment after liver transplantation. Clin Transplant. 2012;26(5):729–35.

    PubMed  Google Scholar 

  162. Wiesner RH, Porayko MK, Dickson ER, Gores GJ, LaRusso NF, Hay JE, et al. Selection and timing of liver transplantation in primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology. 1992;16(5):1290–9.

    PubMed  CAS  Google Scholar 

  163. Kim WR, Therneau TM, Wiesner RH, Poterucha JJ, Benson JT, Malinchoc M, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc. 2000;75(7):688–94.

    PubMed  CAS  Google Scholar 

  164. Freeman RB, Wiesner RH, Edwards E, Harper A, Merion R, Wolfe R. Results of the first year of the new liver allocation plan. Liver Transpl. 2004;10(1):7–15.

    PubMed  Google Scholar 

  165. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl. 2006;12(12):1813–24.

    PubMed  Google Scholar 

  166. Fosby B, Karlsen TH, Melum E. Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol. 2012;18(1):1–15.

    PubMed  Google Scholar 

  167. Rowe IA, Webb K, Gunson BK, Mehta N, Haque S, Neuberger J. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int. 2008;21(5):459–65.

    PubMed  Google Scholar 

  168. Alabraba E, Nightingale P, Gunson B, Hubscher S, Olliff S, Mirza D, et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl. 2009;15(3):330–40.

    PubMed  Google Scholar 

  169. Alexander J, Lord JD, Yeh MM, Cuevas C, Bakthavatsalam R, Kowdley KV. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 2008;14(2):245–51.

    PubMed  Google Scholar 

  170. Jeyarajah DR, Netto GJ, Lee SP, Testa G, Abbasoglu O, Husberg BS, et al. Recurrent primary sclerosing cholangitis after orthotopic liver transplantation: is chronic rejection part of the disease process? Transplantation. 1998;66(10):1300–6.

    PubMed  CAS  Google Scholar 

  171. Khettry U, Keaveny A, Goldar-Najafi A, Lewis WD, Pomfret EA, Pomposelli JJ, et al. Liver transplantation for primary sclerosing cholangitis: a long-term clinicopathologic study. Hum Pathol. 2003;34(11):1127–36.

    PubMed  Google Scholar 

  172. Vera A, Moledina S, Gunson B, Hubscher S, Mirza D, Olliff S, et al. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet. 2002;360(9349):1943–4.

    PubMed  Google Scholar 

  173. Egawa H, Taira K, Teramukai S, Haga H, Ueda Y, Yonezawa A, et al. Risk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation: a single center experience. Dig Dis Sci. 2009;54(6):1347–54.

    PubMed  Google Scholar 

  174. Graziadei IW. Live donor liver transplantation for primary sclerosing cholangitis: is disease recurrence increased? Curr Opin Gastroenterol. 2011;27(3):301–5.

    PubMed  Google Scholar 

  175. Kugelmas M, Spiegelman P, Osgood MJ, Young DA, Trotter JF, Steinberg T, et al. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 2003;9(7):727–32.

    PubMed  Google Scholar 

  176. Campsen J, Zimmerman MA, Trotter JF, Wachs M, Bak T, Steinberg T, et al. Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl. 2008;14(2):181–5.

    PubMed  Google Scholar 

  177. Cholongitas E, Shusang V, Papatheodoridis GV, Marelli L, Manousou P, Rolando N, et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 2008;14(2):138–43.

    PubMed  Google Scholar 

  178. Howell JA, Gow PJ, Angus PW, Jones RM, Wang BZ, Bailey M, et al. Early-onset versus late-onset nonanastomotic biliary strictures post liver transplantation: risk factors reflect different pathogenesis. Transpl Int. 2012;25(7):765–75.

    PubMed  Google Scholar 

  179. Gelley F, Miheller P, Peter A, Telkes G, Nemes B. Activity of ulcerative colitis before and after liver transplantation in primary sclerosing cholangitis: the Hungarian experience. Transplant Proc. 2012;44(7):2164–5.

    PubMed  CAS  Google Scholar 

  180. Navaneethan U, Choudhary M, Venkatesh PG, Lashner BA, Remzi FH, Shen B, et al. The effects of liver transplantation on the clinical course of colitis in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther. 2012; 35:1054–63.

    Google Scholar 

  181. Jorgensen KK, Grzyb K, Lundin KE, Clausen OP, Aamodt G, Schrumpf E, et al. Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients. Inflamm Bowel Dis. 2012;18(3):536–45.

    PubMed  Google Scholar 

  182. Verdonk RC, Dijkstra G, Haagsma EB, Shostrom VK, Van den Berg AP, Kleibeuker JH, et al. Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am J Transplant. 2006;6(6):1422–9.

    PubMed  CAS  Google Scholar 

  183. Bleday R, Lee E, Jessurun J, Heine J, Wong WD. Increased risk of early colorectal neoplasms after hepatic transplant in patients with inflammatory bowel disease [Review]. Dis Colon Rectum. 1993;36(10):908–12.

    PubMed  CAS  Google Scholar 

  184. Vera A, Gunson BK, Ussatoff V, Nightingale P, Candinas D, Radley S, et al. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation. 2003;75(12):1983–8.

    PubMed  Google Scholar 

  185. Loftus Jr EV, Aguilar HI, Sandborn WJ, Tremaine WJ, Krom RA, Zinsmeister AR, et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology. 1998;27(3):685–90.

    PubMed  Google Scholar 

  186. Hanouneh IA, Macaron C, Lopez R, Zein NN, Lashner BA. Risk of colonic neoplasia after liver transplantation for primary sclerosing cholangitis. Inflamm Bowel Dis. 2012;18(2):269–74.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Waehringerguertel 18-20, 1090, Vienna, Austria

    Harald Hofer, Emina Halilbasic, Katharina Staufer & Michael Trauner

Authors
  1. Harald Hofer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emina Halilbasic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katharina Staufer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Trauner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Trauner .

Editor information

Editors and Affiliations

  1. Division of Rheumatology, Allergy and Clinical Immunology, University of California School of Medicine, Davis, California, USA

    M. Eric Gershwin

  2. Medicine and Surgery, Baylor College of Medicine, Houston, Texas, USA

    John M. Vierling

  3. Department of Gastroenterology, Hepatology and Endocrinology, Medical School of Hannover, Germany

    Michael P. Manns

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Hofer, H., Halilbasic, E., Staufer, K., Trauner, M. (2014). Primary Sclerosing Cholangitis (PSC). In: Gershwin, M., Vierling, J., Manns, M. (eds) Liver Immunology. Springer, Cham. https://doi.org/10.1007/978-3-319-02096-9_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-02096-9_20

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-02095-2

  • Online ISBN: 978-3-319-02096-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation